How would you treat: Glucagon-like peptide 1 receptor analogue or sodium-glucose cotransporter 2 inhibitor in chronic coronary syndrome and heart failure in type 2 diabetes?

Q: What is the clinical evidence from this study?

Study design: Case Report. Population: Type 2 diabetes mellitus, coronary artery disease, and heart failure with preserved ejection fraction (n=1). Intervention: SGLT2 inhibitors and GLP-1 receptor agonists.

Tamara Kovačević-Preradović; Željko Živanović; A. Brkic; Ljiljana Kos; Nikola Šobot; Sanja Stojković; Dragan Unčanin

doi:10.5937/siks2011008k

January 1, 2020Srce i krvni sudoviOpen Access

How would you treat: Glucagon-like peptide 1 receptor analogue or sodium-glucose cotransporter 2 inhibitor in chronic coronary syndrome and heart failure in type 2 diabetes?

View Full Paper

Ask AI

Bookmark

Share

Key result

Case highlights the dilemma of choosing between SGLT2 inhibitors and GLP-1 receptor agonists in HFpEF.

n=1

Study Design

Type

Case Report (n=1)

PICO

P

Population

A 58-year-old male with type 2 diabetes, coronary artery disease, and heart failure with preserved ejection fraction.

I

Intervention / Comparator

SGLT2 inhibitors and GLP-1 receptor agonists

Limitations

Lacks evaluation of the long-term effects of the combined use of SGLT2 inhibitors and GLP-1 receptor agonists.
Ongoing clinical trials are still needed to define the role of GLP-1 receptor agonists in individuals with established heart failure.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Case reports highlight treating myocardial infarction complications in diabetes, suggesting improved strategies may reduce mortality.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kovačević-Preradović et al. (2020) conducted a case report in Type 2 diabetes mellitus, coronary artery disease, and heart failure with preserved ejection fraction (n=1). SGLT2 inhibitors and GLP-1 receptor agonists was evaluated. A 58-year-old male patient with type 2 diabetes, coronary artery disease, and heart failure with preserved ejection fraction illustrates the clinical dilemma of choosing between SGLT2 inhibitors and GLP-1 receptor agonists.

synapsesocial.com/papers/697854e0ccb046adae517057 https://doi.org/10.5937/siks2011008k

View Full Paper

Ask AI

Bookmark

Share

How would you treat: Glucagon-like peptide 1 receptor analogue or sodium-glucose cotransporter 2 inhibitor in chronic coronary syndrome and heart failure in type 2 diabetes?

Study Design

PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

How would you treat: Glucagon-like peptide 1 receptor analogue or sodium-glucose cotransporter 2 inhibitor in chronic coronary syndrome and heart failure in type 2 diabetes?

Study Design

PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading